This study has some limitations, including the number of observed events in the relatively short follow-up and sample size (albeit in line with the low prevalence of APS, especially when focusing on subgroups of patients with specific aPL profiles). The gene discussed is FASLG; the disease is autoimmune polyendocrinopathy.